RxDoctor Payments Data

Goshawn Chawla, MD

Child & Adolescent Psychiatry · El Paso, TXNPI 1417277419

Payments from drug & device makers

$1,240in general payments, 2019–2025

Across 30 payments — averaging $41.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$722
  • Teva Pharmaceuticals USA, Inc.$217
  • Acadia Pharmaceuticals Inc$107
  • Johnson & Johnson$92
  • E.r. Squibb & Sons, L.L.C.$67
  • Boehringer Ingelheim$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,240 in reported general payments places this provider in the 70th percentile of 301 child & adolescent psychiatry providers in Texas.

See all child & adolescent psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$176,731
Medicare patients
460
Services billed
1,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$39,115
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$1,846
Oxcarbazepine33$1,281
Aripiprazole31$1,243
Quetiapine Fumarate33$399
Buspirone Hcl41$303
Hydroxyzine Pamoate34$287
Memantine Hcl15$272
Trazodone Hcl46$257
Mirtazapine23$229
Olanzapine21$197
Ropinirole Hcl11$178
Bupropion XlBupropion Hcl14$151
Fluoxetine Hcl14$142
Gabapentin13$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$92$39,11514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 301 child & adolescent psychiatry providers in Texas.

Other child & adolescent psychiatry in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →